April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
The Ability of SWAP and FDT Parameters to Predict Glaucomatous Progression Detected by SAP Guided Progression Analysis
Author Affiliations & Notes
  • A. Tafreshi
    Ophthalmology, Hamilton Glaucoma Center, UCSD, La Jolla, California
  • F. A. Medeiros
    Ophthalmology, Hamilton Glaucoma Center, UCSD, La Jolla, California
    Ophthalmology, University of São Paulo, São Paulo, Brazil
  • L. M. Alencar
    Ophthalmology, Hamilton Glaucoma Center, UCSD, La Jolla, California
    Ophthalmology, University of São Paulo, São Paulo, Brazil
  • C. Bowd
    Ophthalmology, Hamilton Glaucoma Center, UCSD, La Jolla, California
  • L. M. Zangwill
    Ophthalmology, Hamilton Glaucoma Center, UCSD, La Jolla, California
  • C. A. Girkin
    Ophthalmology, Univ of Alabama at Birmingham, Birmingham, Alabama
  • J. M. Liebmann
    Ophthalmology, NYU School of Medicine, New York, New York
  • R. N. Weinreb
    Ophthalmology, Hamilton Glaucoma Center, UCSD, La Jolla, California
  • P. A. Sample
    Ophthalmology, Hamilton Glaucoma Center, UCSD, La Jolla, California
  • Footnotes
    Commercial Relationships  A. Tafreshi, None; F.A. Medeiros, Pfizer Inc., F; Alcon laboratories Inc., F; Carl Zeiss Meditec Inc., F; Pfizer Inc., C; Alcon Laboratories Inc., C; Allergan Inc., C; Pfizer Inc., R; Alcon Laboratories Inc., R; Allergan Inc., R; Reichert Inc., R; L.M. Alencar, None; C. Bowd, Lace Elettronica, F; L.M. Zangwill, Carl Zeiss Meditec Inc., F; Heidelberg Engineering GmbH, F; Topcon Medical Systems Inc., F; Optovue Inc., F; C.A. Girkin, Pfizer Inc., C; Heidelberg Engineering GmbH, R; Merck Inc., R; Alcon Laboratories Inc., C; Allergan Inc., C; Optovue Inc., R; Carl Zeiss Meditec Inc., R; J.M. Liebmann, Carl Zeiss Meditec Inc., F; Diopsys Inc., F; Optovue Inc., F; Topcon Medical Systems Inc., F; Alcon Laboratories Inc., C; Allergan Inc., C; Diopsys Inc., C; Optovue Inc., C; Pfizer Inc., C; Topcon Medical Systems Inc., C; R.N. Weinreb, Carl Zeiss Meditec Inc., F; Heidelberg Engineering GmbH, F; Optovue Inc., F; Topcon Medical Systems Inc., F; Alcon Laboratories Inc., C; Allergan Inc., C; Carl Zeiss Meditec Inc., C; Glaxo, C; Optovue Inc., C; Pfizer Inc., C; Topcon Medical Systems Inc., C; P.A. Sample, Carl Zeiss Meditec Inc., F; Welch-Allyn, F; Haag-Streit, F.
  • Footnotes
    Support  NEI EY11008 (LMZ), NEI EY08208 (PAS), NEI EY14267 (PAS, JML, CAG), EY13959 (CAG), Eyesight Foundation of Alabama (CAG) and glaucoma medications grant (Alcon, Allergan, Pfizer, Merck, SANTEN)
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4000. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Tafreshi, F. A. Medeiros, L. M. Alencar, C. Bowd, L. M. Zangwill, C. A. Girkin, J. M. Liebmann, R. N. Weinreb, P. A. Sample; The Ability of SWAP and FDT Parameters to Predict Glaucomatous Progression Detected by SAP Guided Progression Analysis. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4000.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess whether short-wavelength automated perimetry (SWAP) and frequency doubling technology (FDT) parameters are predictive of progressive glaucomatous visual field loss as assessed by standard automated perimetry (SAP) guided progression analysis (GPA).

Methods: : In the current study, 919 eyes of 621 glaucoma patients and suspects from the longitudinal Diagnostic Innovations in Glaucoma Study (DIGS) and African Descent and Glaucoma Evaluation Study (ADAGES) were tested with SAP, SWAP, and FDT Matrix within 3 months. Glaucomatous "likely progression" was determined using GPA. The associations between baseline SWAP and FDT parameters and glaucoma progression on SAP GPA were investigated by Cox regression models. Multivariable models were adjusted for age, intraocular pressure, central corneal thickness and vertical cup-to-disc ratio. The c-index was used to evaluate and compare the predictive abilities.

Results: : Over a 3.7-year average follow-up period, 47 eyes (5.1%) showed progression. In univariable models, SWAP and FDT PSD were predictive of progression [hazard ratios - HR (95% CI); 1.24 (1.08-1.43) per 1 dB and 1.20 (1.01-1.42) per 1dB, respectively]. In multivariable models, SWAP and FDT MD and PSD were not predictive of glaucomatous progression [HR (95% CI); 1.15 (0.99-1.34) per dB, 1.00 (0.94-1.07) per 1 dB, 0.98 (0.91-1.05) per 1 dB, and 1.11 (0.93-1.32) per 1 dB, respectively]. The c-index values for the multivariable models of SWAP and FDT MD and PSD were 0.657, 0.675, 0.662 and 0.666, respectively.

Conclusions: : Univariable models showed that SWAP and FDT are weakly predictive of glaucomatous visual field loss assessed by SAP GPA in glaucoma suspects and patients. Using multivariable models, SWAP and FDT were not suggestive of glaucomatous progression.

Keywords: visual fields • perimetry 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×